Early health technology assessment of diagnostic cardiology technology for reperfusion VF prediction of STEMI patients indicated for PCI

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F25%3A00379261" target="_blank" >RIV/68407700:21460/25:00379261 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1007/s12553-024-00933-9" target="_blank" >https://doi.org/10.1007/s12553-024-00933-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12553-024-00933-9" target="_blank" >10.1007/s12553-024-00933-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Early health technology assessment of diagnostic cardiology technology for reperfusion VF prediction of STEMI patients indicated for PCI

Popis výsledku v původním jazyce

Purpose The study deals with eHTA of new technology for STEMI patients indicated for PCI treatment, which contains diagnostic of rVF risks and medication to prevent rVF in at-risk patients above standard approved procedure. Due to the recommended medication procedure for STEMI patients with identified high rVF risks during PCI and its effectiveness have not been established the goal is to find out what level of medication effectiveness which will be sufficient for the cost-effectiveness of the new technology. Methods Scenarios where the effectiveness of rVF protecting medication administered to predisposed STEMI patients undergoing PCI varies from 5 to 95% were analyzed. Cost-effectiveness was evaluated by the CEA. Results The determined minimum effectiveness of rVF protecting medication to achieve the technology and procedure cost-effectiveness is 7.54%. Even if medication efficacy is at least 39.58%, the technology is “dominant” and the ICER is in the South-east [SE] quadrant. Conclusions Cost-effectiveness analysis show that for all scenarios modeled, except the 5% medication effectiveness scenario, the technology appears to be cost-effective. so such new technology will probably be very attractive for investors.

Název v anglickém jazyce

Early health technology assessment of diagnostic cardiology technology for reperfusion VF prediction of STEMI patients indicated for PCI

Popis výsledku anglicky

Purpose The study deals with eHTA of new technology for STEMI patients indicated for PCI treatment, which contains diagnostic of rVF risks and medication to prevent rVF in at-risk patients above standard approved procedure. Due to the recommended medication procedure for STEMI patients with identified high rVF risks during PCI and its effectiveness have not been established the goal is to find out what level of medication effectiveness which will be sufficient for the cost-effectiveness of the new technology. Methods Scenarios where the effectiveness of rVF protecting medication administered to predisposed STEMI patients undergoing PCI varies from 5 to 95% were analyzed. Cost-effectiveness was evaluated by the CEA. Results The determined minimum effectiveness of rVF protecting medication to achieve the technology and procedure cost-effectiveness is 7.54%. Even if medication efficacy is at least 39.58%, the technology is “dominant” and the ICER is in the South-east [SE] quadrant. Conclusions Cost-effectiveness analysis show that for all scenarios modeled, except the 5% medication effectiveness scenario, the technology appears to be cost-effective. so such new technology will probably be very attractive for investors.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

20601 - Medical engineering

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Health and Technology

ISSN

2190-7188

e-ISSN

2190-7196

Svazek periodika

15

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

9

Strana od-do

377-385

Kód UT WoS článku

001390194500001

EID výsledku v databázi Scopus

2-s2.0-105002994472